Transparency notification of Schwarz Vermögensverwaltung GmbH & Co, Financière de Tubize SA and UCB SA/NV
Shareholding on 29 September 2011 (according to Article 6 and 14 of the law of 2 May 2007 on the disclosure of large shareholdings).
Brussels (Belgium), October 5, 2011 – 19:00 PM CET - regulated information - As a result of transactions carried out by UCB SA/NV on 29 September 2011 relating to its own securities, UCB SA/NV received on 5 October 2011 various transparency notifications.
On 29 September 2011, UCB SA/NV carried out the following transactions: UCB SA/NV first sold 704.733 UCB SA/NV-shares, and later acquired 1.400.000 options on UCB SA/NV-shares. Afterwards, UCB SA/NV acquired OTC 1.114.259 UCB SA/NV-shares with voting rights from KBC Bank NV.
As a result of these transactions, UCB SA/NV holds more than 3% of its own voting rights (2,18% attached to the shares it holds and 1,20% to the options on its own shares, assuming that all options would be exercised). In addition, UCB SA/NV crosses, together with UCB Fipar SA and UCB SCA the threshold of 5% of the voting rights to UCB SA/NV (3,90% attached to the shares they hold and 1,20% to the options on UCB SA/NV-shares, under the same assumption). This information arises from each of the transparency notifications UCB SA/NV has received.
Furthermore, KBC Bank NV currently no longer holds any UCB SA/NV-shares in concert with Financière de Tubize SA. This has led to a transparency notification. The number of shares held by the concert between Financière de Tubize SA and Schwarz Vermögensverwaltung GmbH & Co KG henceforth reaches 41,44% of the voting rights to UCB SA/NV, and even 42,64% when taking into account the options held by UCB SA/NV on its own shares and once again assuming that all options would be exercised. For this reason, this concert made a transparency notification.
Finally, in order to properly inform the general public, the information relating to all concerts to which Financière de Tubize SA is a party (i.e., the concert with Degroof Corporate Finance SA, Imofig Sa and Levimmo SA; the one with Compar Finance SA; and the one with Pharmahold SA and Cosylva SA) was updated.
A chart with the total number of securities and the percentage of voting rights attached thereto is included in the corporate governance charter of UCB SA/NV, which is published on UCB SA/NV’s website. UCB SA/NV also published the transparency notifications on its website.
UCB S.A./N.V. – Allée de la Recherche, 60 – 1070 Brussels – RPM 0403.053.608
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, firstname.lastname@example.org
For further information
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, Michael.email@example.com
Notes to the editor
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).
Forward looking statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of employees.
Stay up-to-date on the latest news and information from UCB